Scarica l'app Stockscreener
109.86
2.73%
2.92
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Argus raises target for Halozyme Therapeutics stock to USD 127 - AD HOC NEWS
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Halozyme appoints Jim Daly to board of directors - Investing.com
Halozyme adds James Daly to its Board of Directors - TradingView
Halozyme Therapeutics, Inc. Appoints James "Jim" Daly to Its Board of Directors - marketscreener.com
Price to cash flow ratio of Halozyme Therapeutics, Inc. – HAN:RV7 - TradingView
Halozyme Therapeutics, Inc. (HALO) Stock forecasts - Yahoo Finance Australia
Halozyme Therapeutics, Inc. Revenue Breakdown – HAN:RV7 - TradingView
Halozyme Therapeutics, Inc. Actuals & Estimates (HAN:RV7) - TradingView
ETFs Investing in Halozyme Therapeutics, Inc. Stocks - TradingView
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now - Eastern Progress
Halozyme stock falls 2.34% after strong quarterly growth - AD HOC NEWS
$1000 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth This Much Today - Benzinga
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength? - Yahoo Finance
Form 8K Halozyme Therapeutics Inc For: 22 September By Investing.com - Investing.com Canada
Halozyme Therapeutics completes $1.5 billion convertible notes offering By Investing.com - Investing.com Canada
Halozyme Therapeutics completes $1.5 billion convertible notes offering - Investing.com
Halozyme Therapeutics Raises $1.5 Billion in 1.50% Convertible Notes, Adds Capped Calls - TradingView
Halozyme Therapeutics, Inc. (HALO) stock price, news, quote and history - sg.finance.yahoo.com
Halozyme Therapeutics stock rises as $1.3 billion convertible notes fuel growth guidance - AD HOC NEWS
Halozyme (HALO) Just Made A $1.3B Bet On Itself - Yahoo Finance
Latham & Watkins Advises on Halozyme Therapeutics, Inc.’s Upsized US$1.3 Billion Convertible Senior Notes Offering - Latham & Watkins LLP
(HALO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate - Zacks Investment Research
Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost? - Yahoo Finance
Halozyme Therapeutics stock edges higher as investors weigh Q2 growth and pipeline risk - AD HOC NEWS
Halozyme Therapeutics (HALO) Rises 2.53% to $112.45, Testing Upper Half of Recent RangeBear Pennant - careplusvn.com
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) - easternprogress.com
Is Halozyme Therapeutics (HALO) Fully Valued As Growth Calls And Partnerships Draw Fresh Attention? - webull.com
Halozyme Therapeutics Prices $1.3 Billion Convertible Senior Notes with Additional $200 Million Overallotment Option - Kalkine Media
Dynatrace, Cava Group, Halozyme Therapeutics - TradingView
Halozyme Therapeutics, Etsy, Netflix - TradingView
Halozyme Therapeutics stock hits all-time high at 111.56 USD By Investing.com - Investing.com Nigeria
Halozyme Therapeutics stock hits all-time high at 111.56 USD - Investing.com
Halozyme prices $1.3B of 1.50% convertible notes due 2033, upsized with $200M option - TradingView
Halozyme Prices $1.3 Billion Convertible Senior Notes Offering - marketscreener.com
HALO Looks 10.2% Overvalued on GF Value™ - GuruFocus
Halozyme prices $1.3B convertible notes to fund repurchases and growth initiatives - Pluang
Halozyme prices $1.3 billion convertible notes offering - Investing.com
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 - PR Newswire
HALOZYME THERAPEUTICS (NASDAQ: HALO) Announces $1.05 Billion Convertible Senior Notes Offering with $150 Million Option - Kalkine Media
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Prices Upsized $1.3B 1.50% Convertible Notes Due 2033 - TradingView
Halozyme Therapeutics Plans $1.05 Billion Offering of Convertible Notes - marketscreener.com
Halozyme Therapeutics plans a $1.05B convertible notes sale - TradingView
Years of RSU awards set for sale by Halozyme (NASDAQ: HALO) director - stocktitan.net
Halozyme plans $1.05 billion convertible notes offering - Investing.com
Halozyme proposes $1.05B convertible notes due 2033, with $150M option - TradingView
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Plans $1.05B Convertible Notes Due 2033 - TradingView
Is Halozyme Therapeutics (HALO) Fully Priced Ahead Of Its September Conference Run? - Yahoo Finance
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):